The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination
If the prescriber cannot or will not attempt those steps, the patient can consider seeing a healthcare professional who focuses on weight management
That's why IBX offers several benefits* to help members on their weight management journey that include: Outpatient nutrition and behavioral health counseling Reimbursements for fitness center fees, weight management programs, and other health-related programs Lifestyle management programs that offer clinically proven support for weight management, nutrition, stress relief, and more Bariatric surgery for members with health risks from being obese Members should visit the IBX member site to review the different benefits that may be available to them
A: The timing can be personalized based on your physician's advice
Nauck, Diabetes, Obesity, & Metabolism , Occurrence of Nausea, Vomiting and Diarrhea Reported as Adverse Events in Clinical Trials Studying Glucagon-like Peptide-1 Receptor Agonists
This makes it easier for individuals to stick to a calorie-controlled diet
